ClinicalTrials.gg
CompletedNCT05073003Updated Jun 22, 2026Results posted

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants

A Phase 1/2 interventional study of AltSonflex1-2-3 High Dose and AltSonflex1-2-3 Medium Dose in Diarrhoea, sponsored by GlaxoSmithKline. Completed at 2 sites in 2 countries. Open to participants aged 9 Months to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
551
Allocation
Randomized
Ages
9 Months to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Diarrhea with a site in Belgium — 1 open to participants now, 1 under way, none of them phase 3. Diarrhea · Belgium.

Enrollment
Largest of 12
551 · median 284
Started
2021
with 1 other
Phase 1/2
Only one
of the 14
Registered
11th of 14
by date
Lead sponsor
1 of 14
GlaxoSmithKline

Among the 14 studies in Diarrhea with a site in Belgium, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is the only one in phase 1/2, and was the 11th registered.

Diarrhea

879 studies on the registry are indexed under Diarrhea; 77 are open to participants now.

Browse Diarrhea studies →

Open to participants now

1 of the 14 studies in Diarrhea with a site in Belgium is open now. Recruiting first, the newest first:

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.

This study: 9 Months to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diarrhea with a site in Belgium, or all of them as a file.
02

Study summary

The aim of the current clinical study was to evaluate, for the first time in humans (FTIH), the safety and immunogenicity of the altSonflex1-2-3 candidate vaccine against S. sonnei and S. flexneri serotypes 1b, 2a, and 3a. The vaccine was first administered to adults 18 to 50 years of age in Europe. Subsequently, the vaccine was administered to a shigellosis-endemic population in Africa, first to adults 18 to 50 years of age, then to children 24 to 59 months of age, and finally to infants 9 months of age. Infants also received a third vaccination. Three different doses of the vaccine [low, medium, and high amounts of antigen] were evaluated using an age de-escalation approach (from the least vulnerable adult population to the most vulnerable paediatric population). The results of this study allowed the selection of the most appropriate dose for further vaccine development in infants 9 months of age, which was the main target age group for this vaccine.

03

Conditions studied

  • Diarrhoea

Keywords

  • Shigella infection
  • Shigellosis
  • Diarrhoea
  • S. sonnei
  • S. flexneri
  • Low and middle income countries
04

Who can participate

Ages eligible
9 Months to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants:

  • Participants and/or participants' parent(s)/legally acceptable representative(s) (LARs), who, in the opinion of the investigator, could and would comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
  • Written or witnessed/thumb-printed was obtained from the participant/parent(s)/LAR(s) of the participant prior to the performance of any study-specific procedure.
  • Healthy participants, as established by medical history, clinical examination, and laboratory assessment.
  • Participants who satisfied all screening requirements.
  • Participants who were seronegative for and .
  • Participants who were negative for human leukocyte antigen B27 (HLA-B27).

Adults 18 to 50 years of age:

  • A male or female between, and including, 18 and 50 years of age at the time of the first study intervention administration.
  • Female participants of non- may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or .
  • Female participants of childbearing potential may be enrolled in the study, if the participant:

    - has practiced adequate for 1 month prior to study intervention administration, and

    - has a negative pregnancy test on the day of study intervention administration, and

    • has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.
  • Participants seronegative for (HIV).

Children 24 to 59 months of age:

  • A male or female between, and including, 24 and 59 months of age at the time of first vaccination.
  • A normal nutritional Z score (-2 standard deviations or greater).
  • Participants who had previously completed routine childhood vaccinations to the best knowledge of the participant's parent(s)/LAR(s).
  • Participants who were born after a gestation period of ≥37 weeks.
  • Participants who were seronegative for HIV.

Infants 9 months of age:

  • A male or female 9 months of age at the time of first vaccination.
  • A normal nutritional Z score (-2 standard deviations or greater).
  • Participants who had previously completed routine childhood vaccinations to the best knowledge of the participant's parent(s)/LAR(s).
  • Participants who were born after a gestation period of >=37 weeks.
  • Participants who were negative for HIV, as confirmed by deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) testing.

Exclusion criteria

Exclusion Criteria:

All participants:

  • Known exposure to Shigella during the lifetime of the participant, as confirmed during interview with the participant or documented by patient records (e.g., history of microbiologically confirmed Shigella infection), recent travel* (within 2 years) to a country where Shigella or other enteric infections are endemic, or recent occupation* (within 3 years) involving Shigella species.

Exclusion due to travel or occupation was applicable only to adults 18 to 50 years of age in Europe (Stage 1).

  • Progressive, unstable, or uncontrolled clinical conditions.
  • A history (known or suspected) of any reaction or likely to be exacerbated by any component of the study vaccine.
  • Any confirmed or suspected or immunodeficient condition, based on medical history and physical examination (no laboratory testing was required).
  • Hypersensitivity, including allergy, to medicinal products or medical equipment whose use was foreseen in this study.
  • Clinical conditions representing a to IM vaccination and blood draws.
  • Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the investigator, might have interfered with the participant's ability to participate in the study.
  • Acute disease and/or fever (defined as temperature ≥38.0°C) at the time of enrolment*.

The participant could still be enrolled into the study at a time when the acute disease and/or fever had resolved.

  • Any haematological and/or biochemical laboratory abnormality.
  • A confirmed positive COVID-19 test during the period starting 30 days before the first administration of study vaccines (Day -30 to Day 1).
  • Any other clinical condition that, in the opinion of the investigator, might have posed additional risk to the participant due to participation in the study.
  • Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab).
  • Prior receipt of an experimental Shigella vaccine or live Shigella challenge.
  • Use of any or non-registered product (drug, vaccine, or medical device)* other than the study vaccine during the period starting 30 days before the first dose of study intervention (Day -30 to Day 1), or planned use during the study period.

Use of herbs and traditional treatments was not considered an exclusion criterion.

  • Administration of a vaccine not foreseen* by the Study Protocol during the period starting at -21 days before the first dose (-28 days in the case of ) and ending after the last dose of study intervention administration**.

Vaccines allowed by the Protocol included flu and COVID-19 vaccines in all participants and EPI vaccines in children and infants.

*In case of emergency mass vaccination, the time period above could be reduced.

  • Concurrent participation in another clinical study, at any time during the study period, in which the participant had been or would be exposed to an investigational or non-investigational intervention (drug or invasive medical device).
  • Any study personnel or immediate dependents, family, or household members.

Adults 18 to 50 years of age:

  • Acute or chronic illness, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests.
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first vaccine study intervention. For , this meant a prednisone equivalent ≥20 mg/day for adult participants. Inhaled and topical steroids were allowed.
  • Pregnant or lactating females.
  • Females planning to become pregnant or planning to discontinue precautions.
  • A history of or current chronic alcohol consumption and/or drug abuse.

Adults 18 to 50 years of age and children 24 to 59 months of age:

  • Administration of immunoglobulins and/or any blood products or plasma derivatives, or bone marrow transplantation, during the period starting 3 months before the first dose of study vaccine or planned administration during the study period.

Children 24 to 59 months of age and infants 9 months of age:

  • Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination or laboratory screening tests.
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first vaccine dose. For corticosteroids, this meant prednisone ≥0.5 mg/kg/day or 20 mg/day, whichever was the maximum dose for paediatric participants. Inhaled and topical steroids were allowed.
  • A child in care.

Infants 9 months of age:

  • Administration of immunoglobulins and/or any blood products or plasma derivatives, or bone marrow transplantation, from birth or planned administration during the study period.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
551 participants (actual)

Study arms

  • Experimental
    Stage 1 Adults: altSonflex1-2-3 High Dose Group 1

    European participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained 15 micrograms (µg) of O-antigen (OAg) each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).

    Biological: AltSonflex1-2-3 High Dose

  • Experimental
    Stage 1 Adults: altSonflex1-2-3 High Dose Group 2

    European participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 169. High dose of altSonflex1-2-3 contained 15 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).

    Biological: AltSonflex1-2-3 High Dose

  • Placebo comparator
    Stage 1 Adults: Placebo Group

    European participants 18-50 years of age were randomized to receive 1 dose of Placebo on Day 1 and on Day 85 or 169. All participants in Step 1 that received placebo were pooled, as pre-specified in Statistical Analysis Plan.

    Drug: altSonflex Placebo

  • Experimental
    Stage 2 Adults: altSonflex1-2-3 High Dose

    African participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained of 15 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).

    Biological: AltSonflex1-2-3 High Dose

  • Active comparator
    Stage 2 Adults: Control

    African participants 18-50 years of age were randomized to receive 1 dose of MENVEO as comparator on Day 1 and 1 dose of BOOSTRIX as comparator Day 85.

    Biological: Menveo · Combination Product: Boostrix

  • Experimental
    Stage 2 Children: altSonflex1-2-3 Medium Dose

    African participants 24-59 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1 and Day 85. Medium dose of altSonflex1-2-3 contained 7.5 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).

    Biological: AltSonflex1-2-3 Medium Dose

  • Experimental
    Stage 2 Children: altSonflex1-2-3 High Dose

    African participants 24-59 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained 15 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).

    Biological: AltSonflex1-2-3 High Dose

  • Active comparator
    Stage 2 Children: Control

    African participants 24-59 months of age were randomized to receive 1 dose of MENVEO as comparator on Day 1 and 1 dose of TYPHIM VI as comparator on Day 85.

    Biological: Menveo · Combination Product: Typhim-Vi

  • Experimental
    Stage 2 Infants safety cohort: altSonflex1-2-3 Low Dose

    African participants 9 months of age were randomized to receive a low dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. The measles-rubella vaccine (MR-VAC) was administered on Day 29 and Day 281. Low dose of altSonflex1-2-3 contained 3.75 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).

    Biological: AltSonflex1-2-3 Low Dose · Biological: MR-Vac

  • Experimental
    Stage 2 Infants safety cohort: altSonflex1-2-3 Medium Dose

    African participants 9 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was administered on Day 29 and Day 281. Medium dose of altSonflex1-2-3 contained 7.5 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).

    Biological: AltSonflex1-2-3 Medium Dose · Biological: MR-Vac

  • Experimental
    Stage 2 Infants safety cohort: altSonflex1-2-3 High Dose

    African participants 9 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was administered on Day 29 and Day 281. High dose of altSonflex1-2-3 contained 15 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).

    Biological: AltSonflex1-2-3 High Dose · Biological: MR-Vac

  • Active comparator
    Stage 2 Infants safety cohort: Control

    African participants 9 months of age were randomized to receive a dose of MENVEO as comparator on Day 1 and Day 85 and INFRANRIX HEXA as comparator on Day 253. MR-VAC was administered on Day 29 and Day 281.

    Biological: Menveo · Combination Product: INFANRIX HEXA · Biological: MR-Vac

  • Experimental
    Stage 2 Infants dose-finding cohort: altSonflex1-2-3 Low Dose

    African participants 9 months of age were randomized to receive a low dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. Low dose of altSonflex1-2-3 contained 3.75 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).

    Biological: AltSonflex1-2-3 Low Dose · Biological: MR-Vac

  • Experimental
    Stage 2 Infants dose-finding cohort: altSonflex1-2-3 Medium Dose

    African participants 9 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. Medium dose of altSonflex1-2-3 contained 7.5 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).

    Biological: AltSonflex1-2-3 Medium Dose · Biological: MR-Vac

  • Experimental
    Stage 2 Infants dose-finding cohort: altSonflex1-2-3 High Dose

    African participants 9 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. High dose of altSonflex1-2-3 contained 15 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).

    Biological: AltSonflex1-2-3 High Dose · Biological: MR-Vac

  • Active comparator
    Stage 2 Infants dose-finding cohort: Control

    African participants 9 months of age were randomized to receive a dose of MENVEO as comparator on Day 1 and Day 85 and INFRANRIX HEXA as comparator on Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses.

    Biological: Menveo · Combination Product: INFANRIX HEXA · Biological: MR-Vac

Interventions

  • BiologicalAltSonflex1-2-3 High Dose

    2 doses in adults 18-50 years of age and children 24-59 months of age, 3 doses in infants 9 months of age

  • BiologicalAltSonflex1-2-3 Medium Dose

    2 doses in children 24-59 months of age, 3 doses in infants 9 months of age

  • BiologicalAltSonflex1-2-3 Low Dose

    3 doses in infants 9 months of age

  • BiologicalMenveo

    1 dose in adults 18-50 years of age (stage 2) and children 24-59 months of age and 2 doses in infants 9 months of age

  • Combination productBoostrix

    1 dose in adults 18-50 years of age (stage 2)

  • Combination productINFANRIX HEXA

    1 dose in infants 9 months of age

  • Combination productTyphim-Vi

    1 dose in children 24-59 months of age

  • BiologicalMR-Vac

    2 doses in children 24-59 months of age

  • DrugaltSonflex Placebo

    2 doses in adults 18-50 years of age (stage 1)

06

What researchers measure

Primary outcomes

  1. Stage 2: Geometric Mean Concentrations (GMCs) of Anti-serotype Specific Shigella Lipopolysaccharide (LPS)/O-Antigen (OAg) Serum Immunoglobulin G (IgG) in Participants 9 Months of Age in Africa

    Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by enzyme-linked immunosorbent assay (ELISA) and expressed in ELISA units per milliliter (EU/mL) of serum. Four serotypes were tested. Due to the fact, that the Per protocol set (PPS) for Stage 2 Infants - dose finding cohort had less than the 72 participants per group defined in the protocol as a minimum number of participants to ensure power of the analysis, the Stage 2 Infants Safety cohort and Dose-finding cohort were pooled for the statistical analysis as per the Statistical Analysis Plan. As per protocol, statistical analysis was performed only for the S. sonnei serotype, comparing Stage 2 Infants: Pooled groups (medium vs low dose); and Stage 2 Infants Dose-finding groups (high vs low dose). The objective of this outcome measure is to identify the preferred dose of each component of the altSonflex1-2-3 vaccine for infants 9 months of age in Africa, therefore control groups were not analyzed.

    Time frame: At Day 281 (28 days after the third study intervention)

  2. Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Solicited Administration Site Events

    The solicited administration site events assessed were erythema, pain, and swelling.

    Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])

  3. Stage 1: Number of Adults 18 to 50 Years of Age in Europe With Solicited Systemic Events

    The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.

    Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])

  4. Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Unsolicited Adverse Events (AEs)

    An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.

    Time frame: Within 28 days after each study intervention (administered at at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])

  5. Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

    Time frame: From Day 1 to Day 113 and/or Day 197

  6. Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention

    Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 8

  7. Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention

    Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85/Day 169 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 92 (Stage 1 Adults: altSonflex1-2-3 High Dose Group 1), at Day 176 (Stage 1 Adults: altSonflex1-2-3 High Dose Group 2) and at Day 92/Day 176 (Stage 1 Adults: Placebo Group)

  8. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Solicited Administration Site Events

    The solicited administration site events assessed were pain, erythema, and swelling.

    Time frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)

  9. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Solicited Systemic Events

    The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.

    Time frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)

  10. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Unsolicited Adverse Events (AEs)

    An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.

    Time frame: Within 28 days after each study intervention (administered at Day 1 and Day 85)

  11. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

    Time frame: From Day 1 to Day 113

  12. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention

    Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 8

  13. Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention

    Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 92

  14. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Solicited Administration Site Events

    The solicited administration site events assessed were erythema, pain, and swelling.

    Time frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)

  15. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Solicited Systemic Events

    The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.

    Time frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)

  16. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Unsolicited Adverse Events (AEs)

    An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.

    Time frame: Within 28 days after each study intervention (administered at Day 1 and Day 85)

  17. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

    Time frame: From Day 1 to Day 113

  18. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention

    Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 8

  19. Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention

    Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 92

  20. Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Administration Site Events - Infants Safety Cohort

    The solicited administration site events assessed were erythema, pain, and swelling.

    Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)

  21. Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Administration Site Events - Infants Dose-finding Cohort

    The solicited administration site events assessed were erythema, pain, and swelling.

    Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)

  22. Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Systemic Events - Infants Safety Cohort

    The solicited systemic event is fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.

    Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)

  23. Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Systemic Events - Infants Dose-finding Cohort

    The solicited systemic event is fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.

    Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)

  24. Stage 2: Number of Participants 9 Months of Age in Africa With Unsolicited Adverse Events (AEs) - Infants Safety Cohort

    An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.

    Time frame: Within 28 days after each study intervention (administered at Day 1, Day 85 and Day 253)

  25. Stage 2: Number of Participants 9 Months of Age in Africa With Unsolicited Adverse Events (AEs) - Infants Dose-finding Cohort

    An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.

    Time frame: Within 28 days after each study intervention (administered at Day 1, Day 85 and Day 253)

  26. Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Safety Cohort

    An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

    Time frame: From Day 1 to Day 281

  27. Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Dose-finding Cohort

    An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

    Time frame: From Day 1 to Day 281

  28. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention - Infants Safety Cohort

    Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 8

  29. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention - Infants Dose-finding Cohort

    Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 8

  30. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention - Infants Safety Cohort

    Panel tests include measures of ALT, AST, creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 92

  31. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention - Infants Dose-finding Cohort

    Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 92

  32. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Third Study Intervention - Infants Safety Cohort

    Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 260

  33. Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Third Study Intervention - Infants Dose-finding Cohort

    Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

    Time frame: At Day 260

Secondary outcomes

  1. Stage 1: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 18 to 50 Years of Age in Europe

    Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by ELISA and expressed in EU/mL of serum. S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.

    Time frame: At Day 1 and Day 85/Day 169(before each study intervention); at Day 15 (14 days after the first study intervention); at Day 29 and Day 113/Day 197 (28 days after each study intervention)

  2. Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 18 to 50 Years of Age in Africa

    Time frame: At Day 1 and Day 85 (before each study intervention administration) and Day 29 and Day 113 (28 days after each study intervention administration)

  3. Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 24 to 59 Months of Age in Africa

    Time frame: At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)

  4. Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 9 Months of Age in Africa - Infants Safety Cohort

    Time frame: At Day 1, Day 85 and Day 253 (before each study intervention administration) and Day 29, Day 113 and Day 281 (28 days after each study intervention administration)

  5. Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 9 Months of Age in Africa - Dose-finding Cohort

    Time frame: At Day 1, Day 85 and Day 253 (before each study intervention administration) and Day 29, Day 113 and Day 281 (28 days after each study intervention administration)

  6. Stage 1: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg

    Time frame: At Day 1 and Day 85/Day 169 (before each study intervention); at Day 15 (14 days after the first study intervention); at Day 29 and Day 113/Day 197 (28 days after each study intervention)

  7. Stage 2: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg

    Time frame: At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)

  8. Stage 2: Number of Participants 24 to 59 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg

    Time frame: At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)

  9. Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/Oag - Safety Cohort

    Time frame: At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)

  10. Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/Oag - Dose-finding Cohort

    Time frame: At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)

  11. Stage 1: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg

    Time frame: At Day 1 and Day 85/Day 169 (before each study intervention); at Day 15 (14 days after the first study intervention); at Day 29 and Day 113/Day 197 (28 days after each study intervention)

  12. Stage 2: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg

    Time frame: At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)

  13. Stage 2: Number of Participants 24 to 59 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg

    Time frame: At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)

  14. Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg - Safety Cohort

    Time frame: At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)

  15. Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg - Dose-finding Cohort

    Time frame: At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)

  16. Stage 1: Number of Participants 18 to 50 Years of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA

    Time frame: At Day 15 (14 days after the first study intervention) and at Day 29 and Day 113/Day 197 (28 days after each study intervention) compared to baseline (Day 1 and Day 85/Day 169)

  17. Stage 2: Number of Participants 18 to 50 Years of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA

    Time frame: At Day 29 and Day 113 (28 days after each study intervention) compared to baseline (Day 1 and Day 85)

  18. Stage 2: Number of Participants 24 to 59 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA

    Time frame: At Day 29 and Day 113 (28 days after each study intervention) compared to baseline (Day 1 and Day 85)

  19. Stage 2: Number of Participants 9 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA - Safety Cohort

    Time frame: At Day 29, Day 113 and Day 281 (28 days after each study intervention) compared to baseline (Day 1, Day 85 and Day 253)

  20. Stage 2: Number of Participants 9 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA - Dose-finding Cohort

    Time frame: At Day 29, Day 113 and Day 281 (28 days after each study intervention) compared to baseline (Day 1, Day 85 and Day 253)

  21. Stage 2: Anti-measles IgG Concentrations in Participants 9 Months of Age in the Dose-finding Cohort

    Time frame: At Day 1 (before first measles and rubella vaccine (MR-VAC)) and at Day 281 (28 days after the second MR-VAC administration)

  22. Stage 2: Anti-rubella IgG Concentrations in Participants 9 Months of Age in the Dose-finding Groups

    Time frame: At Day 1 (before first measles and rubella vaccine (MR-VAC)) and at Day 281 (28 days after the second MR-VAC administration)

  23. Stage 2: Number of Participants 9 Months of Age in the Dose-finding Groups Achieving Anti-measles IgG Concentrations of ≥150 Milli International Units Per Milliliter (mIU/mL) and ≥200 mIU/mL

    Time frame: Day 281 (28 days after the second MR-VAC administration)

  24. Stage 2: Number of Participants 9 Months of Age in the Dose-finding Groups Achieving Anti-rubella IgG Concentrations of ≥4 mIU/mL and ≥10 mIU/mL

    Time frame: Day 281 (28 days after the second MR-VAC administration)

07

Results

Posted Jun 22, 2026

Participant flow

Out of 551 participants enrolled, 550 started the study and were included in the Exposed set.

Participant flow — Overall Study
MilestoneStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo GroupStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: ControlStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: ControlStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: ControlStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
Started34343410101010201010103082818382
Completed293428101010102098102769717371
Not completed50600000120313101011
Withdrew: Adverse events (including death)2020000000000100
Withdrew: Lost to follow-up0000000000001325
Withdrew: Consent withdrawal, not due to a (serious) adverse event1000000001029455
Withdrew: Migrated / moved from the study area0000000001012220
Withdrew: Other2040000010001011

Outcome measures

PrimaryStage 2: Geometric Mean Concentrations (GMCs) of Anti-serotype Specific Shigella Lipopolysaccharide (LPS)/O-Antigen (OAg) Serum Immunoglobulin G (IgG) in Participants 9 Months of Age in Africa

Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by enzyme-linked immunosorbent assay (ELISA) and expressed in ELISA units per milliliter (EU/mL) of serum. Four serotypes were tested. Due to the fact, that the Per protocol set (PPS) for Stage 2 Infants - dose finding cohort had less than the 72 participants per group defined in the protocol as a minimum number of participants to ensure power of the analysis, the Stage 2 Infants Safety cohort and Dose-finding cohort were pooled for the statistical analysis as per the Statistical Analysis Plan. As per protocol, statistical analysis was performed only for the S. sonnei serotype, comparing Stage 2 Infants: Pooled groups (medium vs low dose); and Stage 2 Infants Dose-finding groups (high vs low dose). The objective of this outcome measure is to identify the preferred dose of each component of the altSonflex1-2-3 vaccine for infants 9 months of age in Africa, therefore control groups were not analyzed.

Time frame:
At Day 281 (28 days after the third study intervention)
Reported as:
Geometric mean · ELISA units per milliliter (EU/mL)
Stage 2: Geometric Mean Concentrations (GMCs) of Anti-serotype Specific Shigella Lipopolysaccharide (LPS)/O-Antigen (OAg) Serum Immunoglobulin G (IgG) in Participants 9 Months of Age in Africa
ELISA units per milliliter (EU/mL)Stage 2 Infants: altSonflex1-2-3 Low Dose PooledStage 2 Infants: altSonflex1-2-3 Medium Dose PooledStage 2 Infants: altSonflex1-2-3 High Dose PooledStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose
S. sonnei Ab IgG379.3 (81.4 to 1766.5)463.5 (95.0 to 2261.3)457.6 (94.7 to 2211.3)437.3 (335.3 to 570.4)577.5 (449.7 to 741.7)584.3 (451.9 to 755.5)
S. flexneri 1b Ab IgG51.1 (39.3 to 66.4)32.1 (25.6 to 40.4)35.6 (28.3 to 44.8)56.6 (44.0 to 72.9)33.1 (25.1 to 43.7)35.1 (27.0 to 45.7)
S. flexneri 2a Ab IgG177.8 (57.4 to 550.6)135.3 (34.0 to 537.9)173.8 (62.4 to 484.0)186.3 (141.2 to 245.8)145.9 (115.2 to 184.9)180.8 (136.9 to 238.7)
S. flexneri 3a Ab IgG32.6 (6.1 to 173.2)24.4 (4.8 to 125.4)27.5 (5.0 to 152.2)39.7 (28.9 to 54.6)30.4 (22.3 to 41.5)36.6 (25.8 to 51.9)
Statistical analysis
  • Stage 2 Infants: altSonflex1-2-3 Low Dose Pooled vs Stage 2 Infants: altSonflex1-2-3 Medium Dose Pooled · t-test, 2 sided · p = 0.273 · Geometric mean concentration ratio: 1.22 · 95% CI 0.85 to 1.75Restricted maximum likelihood was used to estimate the variance components, Kenward-Roger approximation was used to calculate the degrees of freedom.
  • Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose vs Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose · t-test, 2 sided · p = 0.120 (Results are based on a linear mixed model with fixed effect for treatment, timepoint, baseline value, treatment\*timepoint, random effect for cohort and a repeated timepoint effect within a participant under an unstructured covariance matrix.) · Geometric mean concentration ratio: 1.34 · 95% CI 0.93 to 1.93Restricted maximum likelihood was used to estimate the variance components, Kenward-Roger approximation was used to calculate the degrees of freedom.
PrimaryStage 1: Number of Participants 18 to 50 Years of Age in Europe With Solicited Administration Site Events

The solicited administration site events assessed were erythema, pain, and swelling.

Time frame:
Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])
Reported as:
Count of participants · Participants
Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Solicited Administration Site Events
ParticipantsStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo Group
Erythema, Vaccination at Day 1461
Erythema, Vaccination at Day 852——
Erythema, Vaccination at 169—4—
Erythema, Vaccination at Day 85/169——0
Pain, Vaccination at Day 1323316
Pain, Vaccination at Day 8522——
Pain, Vaccination at Day 169—31—
Pain, Vaccination at Day 85/169——8
Swelling, Vaccination at Day 1270
Swelling, Vaccination at Day 855——
Swelling, Vaccination at 169—5—
Swelling, Vaccination at Day 85/169——0
PrimaryStage 1: Number of Adults 18 to 50 Years of Age in Europe With Solicited Systemic Events

The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.

Time frame:
Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])
Reported as:
Count of participants · Participants
Stage 1: Number of Adults 18 to 50 Years of Age in Europe With Solicited Systemic Events
ParticipantsStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo Group
Within 7 days after vaccination at Day 1010
Within 7 days after vaccination at Day 852——
Within 7 days after vaccination at Day 169—1—
Within 7 days after vaccination at Day 85/169——1
PrimaryStage 1: Number of Participants 18 to 50 Years of Age in Europe With Unsolicited Adverse Events (AEs)

An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.

Time frame:
Within 28 days after each study intervention (administered at at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])
Reported as:
Count of participants · Participants
Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Unsolicited Adverse Events (AEs)
ParticipantsStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo Group
Within 28 days after vaccination at Day 1252125
Within 28 days after vaccination at Day 8514——
Within 28 days after vaccination at Day 169—14—
Within 28 days after vaccination at Day 85/169——12
PrimaryStage 1: Number of Participants 18 to 50 Years of Age in Europe With Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

Time frame:
From Day 1 to Day 113 and/or Day 197
Reported as:
Count of participants · Participants
Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Serious Adverse Events (SAEs)
ParticipantsStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo Group
From Day 1 to Day 1130——
From Day 1 to Day 197—1—
From Day 1 to Day 113/197——0
PrimaryStage 1: Number of Participants 18 to 50 Years of Age in Europe With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention

Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 8
Reported as:
Count of participants · Participants
Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention
ParticipantsStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo Group
ALT, Within, Within323330
ALT, Within, Above101
ALT, Above, Within101
ALT, Above, Above012
AST, Within, Within313331
AST, Within, Above003
AST, Above, Within300
AST, Above, Above010
Creatinine, Within, Within333434
Creatinine, Above, Above100
Basophils, Below, Below001
Basophils, Below, Within301
Basophils, Within, Below001
Basophils, Within, Within313331
Basophils, Above, Within010
Eosinophils, Below, Within111
Eosinophils, Within, Below020
Eosinophils, Within, Within323031
Eosinophils, Within, Above001
Eosinophils, Above, Within100
Eosinophils, Above, Above011
Erythrocytes, Below, Below100
Erythrocytes, Below, Within100
Erythrocytes, Within, Below010
Erythrocytes, Within, Within323233
Erythrocytes, Above, Within011
Haematocrit, Below, Below010
Haematocrit, Below, Within101
Haematocrit, Within, Within323233
Haematocrit, Above, Within100
Haematocrit, Above, Above010
Haemoglobin, Below, Below110
Haemoglobin, Below, Within210
Haemoglobin, Within, Below010
Haemoglobin, Within, Within302833
Haemoglobin, Within, Above010
Haemoglobin, Above, Within111
Haemoglobin, Above, Above010
Lymphocytes, Below, Below220
Lymphocytes, Below, Within101
Lymphocytes, Within, Within313231
Lymphocytes, Within, Above002
Monocytes, Below, Within011
Monocytes, Within, Below100
Monocytes, Within, Within333331
Monocytes, Above, Within001
Monocytes, Above, Above001
Neutrophils, Below, Within101
Neutrophils, Below, Above100
Neutrophils, Within, Below021
Neutrophils, Within, Within282832
Neutrophils, Within, Above130
Neutrophils, Above, Within310
Platelets, Below, Within012
Platelets, Within, Within292829
Platelets, Within, Above031
Platelets, Above, Within101
Platelets, Above, Above421
WBC, Below, Within212
WBC, Within, Below140
WBC, Within, Within302932
WBC, Within, Above100
PrimaryStage 1: Number of Participants 18 to 50 Years of Age in Europe With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention

Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85/Day 169 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 92 (Stage 1 Adults: altSonflex1-2-3 High Dose Group 1), at Day 176 (Stage 1 Adults: altSonflex1-2-3 High Dose Group 2) and at Day 92/Day 176 (Stage 1 Adults: Placebo Group)
Reported as:
Count of participants · Participants
Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention
ParticipantsStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo Group
ALT, Within, Within263226
ALT, Within, Above100
ALT, Above, Within111
ALT, Above, Above111
AST, Within, Within273227
AST, Within, Above100
AST, Above, Within111
AST, Above, Above010
Creatinine, Within, Within283427
Creatinine, Within, Above001
Creatinine, Above, Above100
Basophils, Below, Below001
Basophils, Below, Within111
Basophils, Within, Below200
Basophils, Within, Within263325
Basophils, Within, Above001
Eosinophils, Below, Below020
Eosinophils, Within, Below101
Eosinophils, Within, Within253024
Eosinophils, Within, Above111
Eosinophils, Above, Within001
Eosinophils, Above, Above211
Erythrocytes, Within, Below001
Erythrocytes, Within, Within293227
Erythrocytes, Above, Within010
Erythrocytes, Above, Above010
Haematocrit, Below, Below010
Haematocrit, Within, Below010
Haematocrit, Within, Within293128
Haematocrit, Above, Within010
Haemoglobin, Below, Below010
Haemoglobin, Below, Within100
Haemoglobin, Within, Below010
Haemoglobin, Within, Within273028
Haemoglobin, Within, Above100
Haemoglobin, Above, Within020
Lymphocytes, Below, Below111
Lymphocytes, Below, Within220
Lymphocytes, Within, Below030
Lymphocytes, Within, Within252827
Lymphocytes, Within, Above100
Monocytes, Below, Below001
Monocytes, Below, Within111
Monocytes, Within, Within283023
Monocytes, Within, Above020
Monocytes, Above, Within013
Neutrophils, Below, Below001
Neutrophils, Below, Within230
Neutrophils, Within, Below101
Neutrophils, Within, Within262622
Neutrophils, Within, Above021
Neutrophils, Above, Within022
Neutrophils, Above, Above011
Platelets, Below, Within101
Platelets, Within, Below101
Platelets, Within, Within232923
Platelets, Within, Above123
Platelets, Above, Within300
Platelets, Above, Above030
WBC, Below, Below131
WBC, Below, Within220
WBC, Within, Below101
WBC, Within, Within252624
WBC, Within, Above030
WBC, Above, Within001
WBC, Above, Above001
PrimaryStage 2: Number of Participants 18 to 50 Years of Age in Africa With Solicited Administration Site Events

The solicited administration site events assessed were pain, erythema, and swelling.

Time frame:
Within 7 days after each study intervention (administered at Day 1 and Day 85)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Solicited Administration Site Events
ParticipantsStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: Control
Pain, Vaccination at Day 152
Pain, Vaccination at Day 8543
Erythema, Vaccination at Day 100
Erythema, Vaccination at Day 8500
Swelling, Vaccination at Day 100
Swelling, Vaccination at Day 8500
PrimaryStage 2: Number of Participants 18 to 50 Years of Age in Africa With Solicited Systemic Events

The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.

Time frame:
Within 7 days after each study intervention (administered at Day 1 and Day 85)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Solicited Systemic Events
ParticipantsStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: Control
Vaccination at Day 100
Vaccination at Day 8500
PrimaryStage 2: Number of Participants 18 to 50 Years of Age in Africa With Unsolicited Adverse Events (AEs)

An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.

Time frame:
Within 28 days after each study intervention (administered at Day 1 and Day 85)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Unsolicited Adverse Events (AEs)
ParticipantsStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: Control
Vaccination at Day 121
Vaccination at Day 8522
PrimaryStage 2: Number of Participants 18 to 50 Years of Age in Africa With Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

Time frame:
From Day 1 to Day 113
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Serious Adverse Events (SAEs)
ParticipantsStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: Control
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Serious Adverse Events (SAEs)00
PrimaryStage 2: Number of Participants 18 to 50 Years of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention

Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 8
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention
ParticipantsStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: Control
ALT, Within, Below01
ALT, Within, Within109
AST, Within, Within1010
Creatinine, Below, Below66
Creatinine, Below, Within10
Creatinine, Within, Below01
Creatinine, Within, Within33
Basophils, Within, Within1010
Eosinophils, Within, Below01
Eosinophils, Within, Within109
Erythrocytes, Within, Within1010
Haematocrit, Within, Within1010
Haemoglobin, Within, Within1010
Lymphocytes, Below, Within02
Lymphocytes, Within, Within98
Lymphocytes, Above, Above10
Monocytes, Within, Within97
Monocytes, Within, Above01
Monocytes, Above, Above12
Neutrophils, Within, Within99
Neutrophils, Within, Above11
Platelets, Within, Within1010
WBC, Below, Within01
WBC, Within, Within88
WBC, Within, Above11
WBC, Above, Above10
PrimaryStage 2: Number of Participants 18 to 50 Years of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention

Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 92
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention
ParticipantsStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: Control
ALT, Within, Within910
ALT, Within, Above10
AST, Below, Within10
AST, Within, Within810
AST, Within, Above10
Creatinine, Below, Below64
Creatinine, Within, Below12
Creatinine, Within, Within34
Basophils, Within, Within1010
Eosinophils, Below, Within01
Eosinophils, Within, Within109
Erythrocytes, Within, Within1010
Haematocrit, Within, Within1010
Haemoglobin, Within, Within1010
Lymphocytes, Below, Within01
Lymphocytes, Within, Within99
Lymphocytes, Above, Above10
Monocytes, Within, Within79
Monocytes, Within, Above21
Monocytes, Above, Within10
Neutrophils, Within, Within810
Neutrophils, Within, Above10
Neutrophils, Above, Within10
Platelets, Within, Within910
Platelets, Within, Above10
WBC, Within, Within810
WBC, Within, Above10
WBC, Above, Within10
PrimaryStage 2: Number of Participants 24 to 59 Months of Age in Africa With Solicited Administration Site Events

The solicited administration site events assessed were erythema, pain, and swelling.

Time frame:
Within 7 days after each study intervention (administered at Day 1 and Day 85)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Solicited Administration Site Events
ParticipantsStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: Control
Erythema, Vaccination at Day 1110
Erythema, Vaccination at Day 85100
Pain, Vaccination at Day 1623
Pain, Vaccination at Day 85723
Swelling, Vaccination at Day 1110
Swelling, Vaccination at Day 85100
PrimaryStage 2: Number of Participants 24 to 59 Months of Age in Africa With Solicited Systemic Events

The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.

Time frame:
Within 7 days after each study intervention (administered at Day 1 and Day 85)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Solicited Systemic Events
ParticipantsStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: Control
Vaccination at Day 1110
Vaccination at Day 85123
PrimaryStage 2: Number of Participants 24 to 59 Months of Age in Africa With Unsolicited Adverse Events (AEs)

An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.

Time frame:
Within 28 days after each study intervention (administered at Day 1 and Day 85)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Unsolicited Adverse Events (AEs)
ParticipantsStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: Control
Vaccination at Day 1438
Vaccination at Day 85203
PrimaryStage 2: Number of Participants 24 to 59 Months of Age in Africa With Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

Time frame:
From Day 1 to Day 113
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Serious Adverse Events (SAEs)
ParticipantsStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: Control
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Serious Adverse Events (SAEs)000
PrimaryStage 2: Number of Participants 24 to 59 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention

Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 8
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention
ParticipantsStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: Control
ALT, Within, Within8916
ALT, Within, Above011
ALT, Above, Within002
ALT, Above, Above201
AST, Within, Within81020
AST, Above, Within200
Creatinine, Below, Below8917
Creatinine, Below, Within100
Creatinine, Within, Below111
Creatinine, Within, Within001
Creatinine, Above, Within001
Basophils, Within, Below001
Basophils, Within, Within91016
Basophils, Within, Above102
Basophils, Above, Within001
Eosinophils, Below, Within100
Eosinophils, Within, Below001
Eosinophils, Within, Within5612
Eosinophils, Within, Above001
Eosinophils, Above, Within011
Eosinophils, Above, Above435
Erythrocytes, Within, Within8912
Erythrocytes, Within, Above100
Erythrocytes, Above, Within015
Erythrocytes, Above, Above103
Haematocrit, Below, Below010
Haematocrit, Within, Within8714
Haematocrit, Within, Above001
Haematocrit, Above, Within225
Haemoglobin, Below, Below010
Haemoglobin, Below, Within100
Haemoglobin, Within, Below001
Haemoglobin, Within, Within7718
Haemoglobin, Above, Within120
Haemoglobin, Above, Above101
Lymphocytes, Within, Within778
Lymphocytes, Within, Above102
Lymphocytes, Above, Within217
Lymphocytes, Above, Above023
Monocytes, Within, Within9813
Monocytes, Within, Above123
Monocytes, Above, Within001
Monocytes, Above, Above003
Neutrophils, Below, Below001
Neutrophils, Below, Within202
Neutrophils, Within, Below201
Neutrophils, Within, Within61016
Platelets, Within, Within134
Platelets, Within, Above542
Platelets, Above, Within004
Platelets, Above, Above4310
WBC, Below, Within100
WBC, Within, Within91019
WBC, Above, Above001
PrimaryStage 2: Number of Participants 24 to 59 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention

Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 92
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention
ParticipantsStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: Control
ALT, Within, Within9515
ALT, Within, Above002
ALT, Above, Within021
ALT, Above, Above132
AST, Within, Within101019
AST, Within, Above001
Creatinine, Below, Below10818
Creatinine, Within, Below022
Basophils, Within, Within9920
Basophils, Above, Within100
Basophils, Above, Above010
Eosinophils, Within, Below100
Eosinophils, Within, Within6816
Eosinophils, Within, Above101
Eosinophils, Above, Above223
Erythrocytes, Below, Within100
Erythrocytes, Within, Within7817
Erythrocytes, Within, Above101
Erythrocytes, Above, Within010
Erythrocytes, Above, Above112
Haematocrit, Below, Below100
Haematocrit, Below, Within001
Haematocrit, Within, Within91019
Haemoglobin, Below, Below101
Haemoglobin, Within, Below001
Haemoglobin, Within, Within9818
Haemoglobin, Above, Within020
Lymphocytes, Within, Within7614
Lymphocytes, Within, Above002
Lymphocytes, Above, Within323
Lymphocytes, Above, Above021
Monocytes, Below, Within010
Monocytes, Within, Within9713
Monocytes, Within, Above102
Monocytes, Above, Within004
Monocytes, Above, Above021
Neutrophils, Below, Below200
Neutrophils, Below, Within101
Neutrophils, Within, Below001
Neutrophils, Within, Within51018
Neutrophils, Within, Above200
Platelets, Within, Within337
Platelets, Within, Above115
Platelets, Above, Within212
Platelets, Above, Above456
WBC, Below, Within200
WBC, Within, Within71019
WBC, Above, Above101
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Solicited Administration Site Events - Infants Safety Cohort

The solicited administration site events assessed were erythema, pain, and swelling.

Time frame:
Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Administration Site Events - Infants Safety Cohort
ParticipantsStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: Control
Erythema, Vaccination at Day 10031
Erythema, Vaccination at Day 850120
Erythema, Vaccination at Day 2530040
Pain, Vaccination at Day 12373
Pain, Vaccination at Day 852363
Pain, Vaccination at Day 2532476
Swelling, Vaccination at Day 10142
Swelling, Vaccination at Day 850121
Swelling, Vaccination at Day 2531053
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Solicited Administration Site Events - Infants Dose-finding Cohort

The solicited administration site events assessed were erythema, pain, and swelling.

Time frame:
Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Administration Site Events - Infants Dose-finding Cohort
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
Erythema, Vaccination at Day 1169219
Erythema, Vaccination at Day 851112114
Erythema, Vaccination at Day 25367118
Pain, Vaccination at Day 140424314
Pain, Vaccination at Day 8534364320
Pain, Vaccination at Day 25327394126
Swelling, Vaccination at Day 12121219
Swelling, Vaccination at Day 851920222
Swelling, Vaccination at Day 25315121714
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Solicited Systemic Events - Infants Safety Cohort

The solicited systemic event is fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.

Time frame:
Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Systemic Events - Infants Safety Cohort
ParticipantsStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: Control
Vaccination at Day 13145
Vaccination at Day 852112
Vaccination at Day 2531224
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Solicited Systemic Events - Infants Dose-finding Cohort

The solicited systemic event is fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.

Time frame:
Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Systemic Events - Infants Dose-finding Cohort
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
Vaccination at Day 12718237
Vaccination at Day 8517131017
Vaccination at Day 2532116229
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Unsolicited Adverse Events (AEs) - Infants Safety Cohort

An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.

Time frame:
Within 28 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Unsolicited Adverse Events (AEs) - Infants Safety Cohort
ParticipantsStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: Control
Vaccination at Day 123417
Vaccination at Day 8514610
Vaccination at Day 2534244
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Unsolicited Adverse Events (AEs) - Infants Dose-finding Cohort

An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.

Time frame:
Within 28 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Unsolicited Adverse Events (AEs) - Infants Dose-finding Cohort
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
Vaccination at Day 135373441
Vaccination at Day 8523253128
Vaccination at Day 25321293126
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Safety Cohort

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

Time frame:
From Day 1 to Day 281
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Safety Cohort
ParticipantsStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: Control
Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Safety Cohort0001
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Dose-finding Cohort

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

Time frame:
From Day 1 to Day 281
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Dose-finding Cohort
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Dose-finding Cohort2141
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention - Infants Safety Cohort

Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 8
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention - Infants Safety Cohort
ParticipantsStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: Control
ALT, Below, Within0010
ALT, Within, Within109929
ALT, Within, Above0001
AST, Within, Within1091030
Creatinine, Below, Below1091030
Basophils, Within, Within801018
Basophils, Within, Above1002
Basophils, Above, Within1101
Basophils, Above, Above0809
Eosinophils, Within, Within1081028
Eosinophils, Above, Above0102
Erythrocytes, Within, Within89924
Erythrocytes, Within, Above0011
Erythrocytes, Above, Within2001
Erythrocytes, Above, Above0004
Haematocrit, Below, Below1001
Haematocrit, Below, Within1011
Haematocrit, Within, Below1100
Haematocrit, Within, Within78825
Haematocrit, Within, Above0010
Haematocrit, Above, Within0001
Haematocrit, Above, Above0002
Haemoglobin, Below, Below2001
Haemoglobin, Below, Within1011
Haemoglobin, Within, Below1314
Haemoglobin, Within, Within66623
Haemoglobin, Within, Above0011
Haemoglobin, Above, Within0010
Lymphocytes, Within, Within85915
Lymphocytes, Within, Above1115
Lymphocytes, Above, Within1103
Lymphocytes, Above, Above0207
Monocytes, Below, Below0100
Monocytes, Below, Within0011
Monocytes, Within, Within77623
Monocytes, Within, Above0013
Monocytes, Above, Within0122
Monocytes, Above, Above3001
Neutrophils, Below, Below0001
Neutrophils, Below, Within2022
Neutrophils, Within, Below1003
Neutrophils, Within, Within69824
Neutrophils, Above, Within1000
Platelets, Within, Below0001
Platelets, Within, Within1122
Platelets, Within, Above2048
Platelets, Above, Within3003
Platelets, Above, Above48416
WBC, Below, Within0011
WBC, Within, Below0001
WBC, Within, Within87922
WBC, Within, Above1004
WBC, Above, Within0100
WBC, Above, Above1102
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention - Infants Dose-finding Cohort

Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 8
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention - Infants Dose-finding Cohort
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
ALT, Within, Within77757980
ALT, Within, Above1121
ALT, Above, Within1010
AST, Within, Within76767881
AST, Within, Above3020
AST, Above, Within0020
Creatinine, Below, Below79768181
Creatinine, Within, Below0010
Potassium, Below, Within0001
Potassium, Within, Below0010
Potassium, Within, Within79768178
Potassium, Within, Above0001
Potassium, Above, Within0001
Sodium, Within, Within40353937
Sodium, Within, Above14201919
Sodium, Above, Within8111414
Sodium, Above, Above17101011
Urea, Below, Below31293625
Urea, Below, Within13131614
Urea, Within, Below10141115
Urea, Within, Within25201927
Basophils, Within, Within69707368
Basophils, Within, Above2225
Basophils, Above, Within5476
Basophils, Above, Above3002
Eosinophils, Below, Within0231
Eosinophils, Within, Below4313
Eosinophils, Within, Within70657366
Eosinophils, Within, Above2103
Eosinophils, Above, Within2324
Eosinophils, Above, Above1234
Erythrocytes, Below, Below1210
Erythrocytes, Below, Within0130
Erythrocytes, Within, Below1111
Erythrocytes, Within, Within57455253
Erythrocytes, Within, Above4775
Erythrocytes, Above, Within8555
Erythrocytes, Above, Above8151317
Haematocrit, Below, Below4001
Haematocrit, Below, Within1321
Haematocrit, Within, Below2224
Haematocrit, Within, Within62647366
Haematocrit, Within, Above0112
Haematocrit, Above, Within9425
Haematocrit, Above, Above1222
Haemoglobin, Below, Below7343
Haemoglobin, Below, Within5342
Haemoglobin, Within, Below4925
Haemoglobin, Within, Within58586867
Haemoglobin, Within, Above0120
Haemoglobin, Above, Within4103
Haemoglobin, Above, Above1121
Lymphocytes, Below, Within0001
Lymphocytes, Within, Within51545851
Lymphocytes, Within, Above2363
Lymphocytes, Above, Within79814
Lymphocytes, Above, Above19101012
Monocytes, Within, Below0001
Monocytes, Within, Within50535150
Monocytes, Within, Above23161918
Monocytes, Above, Within2145
Monocytes, Above, Above4687
Neutrophils, Below, Below7477
Neutrophils, Below, Within7666
Neutrophils, Within, Below12161211
Neutrophils, Within, Within52495656
Neutrophils, Within, Above0110
Neutrophils, Above, Within1001
Platelets, Below, Above1000
Platelets, Within, Within12191418
Platelets, Within, Above1114126
Platelets, Above, Within14101516
Platelets, Above, Above41334141
WBC, Below, Below2111
WBC, Below, Within0442
WBC, Within, Below4653
WBC, Within, Within54515560
WBC, Within, Above2532
WBC, Above, Within96107
WBC, Above, Above8346
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention - Infants Safety Cohort

Panel tests include measures of ALT, AST, creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 92
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention - Infants Safety Cohort
ParticipantsStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: Control
ALT, Below, Below0010
ALT, Within, Within88928
ALT, Above, Within1000
AST, Within, Within88928
AST, Within, Above0010
AST, Above, Above1000
Creatinine, Below, Below981028
Potassium, Within, Within——26
Potassium, Within, Above——43
Potassium, Above, Within——20
Potassium, Above, Above——21
Sodium, Within, Within——59
Sodium, Within, Above——21
Sodium, Above, Within——30
Urea, Below, Below——73
Urea, Below, Within——03
Urea, Within, Below——11
Urea, Within, Within——23
Basophils, Within, Within13612
Basophils, Within, Above1325
Basophils, Above, Within0111
Basophils, Above, Above71110
Eosinophils, Within, Below0001
Eosinophils, Within, Within861024
Eosinophils, Within, Above1001
Eosinophils, Above, Within0101
Eosinophils, Above, Above0101
Erythrocytes, Below, Below0001
Erythrocytes, Within, Below0001
Erythrocytes, Within, Within65719
Erythrocytes, Within, Above1101
Erythrocytes, Above, Within0012
Erythrocytes, Above, Above2224
Haematocrit, Below, Below0010
Haematocrit, Below, Within1000
Haematocrit, Within, Below3001
Haematocrit, Within, Within55821
Haematocrit, Within, Above0003
Haematocrit, Above, Within0302
Haematocrit, Above, Above0011
Haemoglobin, Below, Below4121
Haemoglobin, Below, Within1000
Haemoglobin, Within, Below0001
Haemoglobin, Within, Within47726
Haemoglobin, Above, Above0010
Lymphocytes, Within, Within85714
Lymphocytes, Within, Above0013
Lymphocytes, Above, Within0101
Lymphocytes, Above, Above12210
Monocytes, Below, Within0001
Monocytes, Within, Below0012
Monocytes, Within, Within96824
Monocytes, Within, Above0210
Monocytes, Above, Above0001
Neutrophils, Below, Below1011
Neutrophils, Below, Within1112
Neutrophils, Below, Above0100
Neutrophils, Within, Below0102
Neutrophils, Within, Within75822
Neutrophils, Within, Above0001
Platelets, Within, Within1227
Platelets, Within, Above1002
Platelets, Above, Within0004
Platelets, Above, Above76815
WBC, Below, Below0011
WBC, Below, Within0001
WBC, Within, Within84618
WBC, Within, Above1322
WBC, Above, Within0005
WBC, Above, Above0111
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention - Infants Dose-finding Cohort

Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 92
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention - Infants Dose-finding Cohort
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
ALT, Below, Below0100
ALT, Below, Within0010
ALT, Within, Below0002
ALT, Within, Within70687168
ALT, Within, Above2203
ALT, Above, Within0120
AST, Within, Within69717372
AST, Within, Above2100
AST, Above, Within1000
AST, Above, Above0011
Creatinine, Below, Below72717472
Creatinine, Below, Within0101
Potassium, Within, Within18161819
Potassium, Within, Above24263428
Potassium, Above, Within98210
Potassium, Above, Above21222016
Sodium, Within, Within48535452
Sodium, Within, Above7588
Sodium, Above, Within17111013
Sodium, Above, Above0320
Urea, Below, Below27243224
Urea, Below, Within912711
Urea, Below, Above0100
Urea, Within, Below13151313
Urea, Within, Within23202225
Basophils, Below, Within0100
Basophils, Within, Below0002
Basophils, Within, Within58586454
Basophils, Within, Above8378
Basophils, Above, Within5525
Basophils, Above, Above1514
Eosinophils, Below, Within0010
Eosinophils, Within, Below1211
Eosinophils, Within, Within61606261
Eosinophils, Within, Above2124
Eosinophils, Above, Within6012
Eosinophils, Above, Above2975
Erythrocytes, Below, Within1100
Erythrocytes, Within, Below0020
Erythrocytes, Within, Within48454450
Erythrocytes, Within, Above5253
Erythrocytes, Above, Within5347
Erythrocytes, Above, Above13211913
Haematocrit, Below, Below1012
Haematocrit, Below, Within1200
Haematocrit, Within, Below3223
Haematocrit, Within, Within60605762
Haematocrit, Within, Above4051
Haematocrit, Above, Within0532
Haematocrit, Above, Above3363
Haemoglobin, Below, Below7754
Haemoglobin, Below, Within2311
Haemoglobin, Within, Below5247
Haemoglobin, Within, Within54565957
Haemoglobin, Within, Above1111
Haemoglobin, Above, Within2212
Haemoglobin, Above, Above1131
Lymphocytes, Within, Below0001
Lymphocytes, Within, Within38434436
Lymphocytes, Within, Above1311119
Lymphocytes, Above, Within651011
Lymphocytes, Above, Above1513916
Monocytes, Below, Within1000
Monocytes, Within, Below0002
Monocytes, Within, Within52476062
Monocytes, Within, Above71582
Monocytes, Above, Within9734
Monocytes, Above, Above3333
Neutrophils, Below, Below1135
Neutrophils, Below, Within67116
Neutrophils, Within, Below5732
Neutrophils, Within, Within57535460
Neutrophils, Within, Above2210
Neutrophils, Above, Within1210
Neutrophils, Above, Above0010
Platelets, Within, Within9151115
Platelets, Within, Above1014165
Platelets, Above, Below1000
Platelets, Above, Within8677
Platelets, Above, Above44374046
WBC, Below, Within3122
WBC, Within, Below3113
WBC, Within, Within47485653
WBC, Within, Above6957
WBC, Above, Within5632
WBC, Above, Above8776
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Third Study Intervention - Infants Safety Cohort

Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 260
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Third Study Intervention - Infants Safety Cohort
ParticipantsStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: Control
ALT, Within, Within98927
ALT, Above, Above0001
AST, Within, Within98928
Creatinine, Below, Below88928
Creatinine, Within, Below1000
Potassium, Within, Within13311
Potassium, Within, Above3105
Potassium, Above, Within1137
Potassium, Above, Above4335
Sodium, Within, Within48618
Sodium, Within, Above2002
Sodium, Above, Within1035
Sodium, Above, Above2003
Urea, Below, Below3259
Urea, Below, Within3112
Urea, Within, Below1114
Urea, Within, Within24213
Basophils, Within, Within57823
Basophils, Within, Above2003
Basophils, Above, Within2012
Basophils, Above, Above0100
Eosinophils, Below, Within0002
Eosinophils, Within, Within87922
Eosinophils, Within, Above1001
Eosinophils, Above, Above0103
Erythrocytes, Below, Below0001
Erythrocytes, Within, Within64720
Erythrocytes, Within, Above1100
Erythrocytes, Above, Within1223
Erythrocytes, Above, Above1104
Haematocrit, Below, Below0002
Haematocrit, Below, Within0001
Haematocrit, Within, Within76816
Haematocrit, Within, Above1102
Haematocrit, Above, Within1102
Haematocrit, Above, Above0015
Haemoglobin, Below, Below0023
Haemoglobin, Below, Within0002
Haemoglobin, Within, Below1001
Haemoglobin, Within, Within88617
Haemoglobin, Within, Above0002
Haemoglobin, Above, Within0002
Haemoglobin, Above, Above0011
Lymphocytes, Within, Within66621
Lymphocytes, Within, Above2102
Lymphocytes, Above, Within1112
Lymphocytes, Above, Above0023
Monocytes, Below, Within1002
Monocytes, Within, Below0010
Monocytes, Within, Within78622
Monocytes, Within, Above1022
Monocytes, Above, Within0001
Monocytes, Above, Above0001
Neutrophils, Below, Below0001
Neutrophils, Below, Within0121
Neutrophils, Within, Below1012
Neutrophils, Within, Within85624
Neutrophils, Within, Above0200
Platelets, Below, Within0100
Platelets, Within, Within2226
Platelets, Within, Above0035
Platelets, Above, Within2125
Platelets, Above, Above54212
WBC, Below, Below0010
WBC, Below, Within1220
WBC, Within, Below0003
WBC, Within, Within74318
WBC, Within, Above1123
WBC, Above, Within0103
WBC, Above, Above0011
PrimaryStage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Third Study Intervention - Infants Dose-finding Cohort

Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Time frame:
At Day 260
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Third Study Intervention - Infants Dose-finding Cohort
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
ALT, Below, Within1212
ALT, Within, Below2100
ALT, Within, Within64676965
ALT, Within, Above1030
ALT, Above, Within1100
ALT, Above, Above0004
AST, Within, Within68717170
AST, Within, Above1010
AST, Above, Within0010
AST, Above, Above0001
Creatinine, Below, Below68707371
Creatinine, Below, Within0100
Creatinine, Within, Below1000
Potassium, Within, Within26282521
Potassium, Within, Above12182323
Potassium, Above, Within118710
Potassium, Above, Above20171817
Sodium, Below, Within1242
Sodium, Within, Below0010
Sodium, Within, Within55615563
Sodium, Within, Above4472
Sodium, Above, Within8364
Sodium, Above, Above1100
Urea, Below, Below18151613
Urea, Below, Within1261112
Urea, Within, Below1014145
Urea, Within, Within29363241
Basophils, Below, Within0001
Basophils, Within, Within53546253
Basophils, Within, Above7848
Basophils, Above, Within6663
Basophils, Above, Above3316
Eosinophils, Below, Within1103
Eosinophils, Within, Below0220
Eosinophils, Within, Within59585956
Eosinophils, Within, Above2422
Eosinophils, Above, Within2133
Eosinophils, Above, Above5577
Erythrocytes, Below, Below0100
Erythrocytes, Within, Within44394644
Erythrocytes, Within, Above4555
Erythrocytes, Above, Within8245
Erythrocytes, Above, Above13241817
Haematocrit, Below, Below2200
Haematocrit, Below, Within1101
Haematocrit, Within, Below0100
Haematocrit, Within, Within55555657
Haematocrit, Within, Above1791
Haematocrit, Above, Within5227
Haematocrit, Above, Above5365
Haemoglobin, Below, Below6444
Haemoglobin, Below, Within3303
Haemoglobin, Within, Below2521
Haemoglobin, Within, Within53525759
Haemoglobin, Within, Above1241
Haemoglobin, Above, Within2142
Haemoglobin, Above, Above2421
Lymphocytes, Within, Within43575848
Lymphocytes, Within, Above13658
Lymphocytes, Above, Within4388
Lymphocytes, Above, Above9527
Monocytes, Below, Below1000
Monocytes, Below, Within1021
Monocytes, Within, Below1102
Monocytes, Within, Within54616362
Monocytes, Within, Above7353
Monocytes, Above, Within4422
Monocytes, Above, Above1211
Neutrophils, Below, Below5101
Neutrophils, Below, Within4596
Neutrophils, Within, Below3355
Neutrophils, Within, Within55605858
Neutrophils, Within, Above1001
Neutrophils, Above, Within1210
Platelets, Below, Below0010
Platelets, Below, Within0010
Platelets, Within, Within17211916
Platelets, Within, Above10181711
Platelets, Above, Within8786
Platelets, Above, Above34252738
WBC, Below, Below1020
WBC, Below, Within4362
WBC, Within, Below1210
WBC, Within, Within44515353
WBC, Within, Above6626
WBC, Above, Within4766
WBC, Above, Above9234
SecondaryStage 1: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 18 to 50 Years of Age in Europe

Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by ELISA and expressed in EU/mL of serum. S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.

Time frame:
At Day 1 and Day 85/Day 169(before each study intervention); at Day 15 (14 days after the first study intervention); at Day 29 and Day 113/Day 197 (28 days after each study intervention)
Reported as:
Geometric mean · EU/mL
Stage 1: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 18 to 50 Years of Age in Europe
EU/mLStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo Group
S sonnei Ab IgG, Day 115.3 (10.8 to 21.8)8.9 (6.9 to 11.5)21.0 (13.2 to 33.6)
S sonnei Ab IgG, Day 15307.5 (167.3 to 565.2)170.7 (98.2 to 296.5)18.4 (11.6 to 29.3)
S sonnei Ab IgG, Day 29325.3 (181.6 to 582.8)172.1 (96.7 to 306.4)18.1 (11.5 to 28.6)
S sonnei Ab IgG, Day 85287.6 (144.1 to 574.1)——
S sonnei Ab IgG, Day 169—94.8 (55.2 to 162.9)—
S sonnei Ab IgG, Day 85/169——19.0 (11.1 to 32.3)
S sonnei Ab IgG, Day 113387.8 (206.6 to 727.8)——
S sonnei Ab IgG, Day 197—167.2 (104.3 to 267.9)—
S sonnei Ab IgG, Day 113/197——19.9 (11.8 to 33.7)
S flexneri 1b Ab IgG, Day 123.5 (13.6 to 40.5)22.9 (13.9 to 37.8)26.9 (15.3 to 47.3)
S flexneri 1b Ab IgG, Day 15123.1 (71.8 to 211.1)102.1 (63.8 to 163.5)27.4 (16.1 to 46.7)
S flexneri 1b Ab IgG, Day 29118.3 (70.5 to 198.5)90.2 (55.9 to 145.5)27.0 (15.8 to 46.3)
S flexneri 1b Ab IgG, Day 8579.1 (45.3 to 138.1)——
S flexneri 1b Ab IgG, Day 169—48.5 (30.1 to 78.0)—
S flexneri 1b Ab IgG, Day 85/169——27.2 (15.5 to 47.7)
S flexneri 1b Ab IgG, Day 113129.7 (79.6 to 211.5)——
S flexneri 1b Ab IgG, Day 197—73.0 (48.6 to 109.7)—
S flexneri 1b Ab IgG, Day 113/197——26.1 (14.6 to 46.9)
S flexneri 2a Ab IgG, Day 133.3 (23.1 to 47.9)32.7 (22.2 to 48.2)44.5 (27.3 to 72.6)
S flexneri 2a Ab IgG, Day 15608.0 (432.4 to 854.9)635.2 (459.5 to 878.1)44.3 (27.4 to 71.6)
S flexneri 2a Ab IgG, Day 29545.8 (393.1 to 757.6)582.6 (424.1 to 800.4)42.8 (26.3 to 69.5)
S flexneri 2a Ab IgG, Day 85411.8 (300.4 to 564.6)——
S flexneri 2a Ab IgG, Day 169—364.9 (259.9 to 512.5)—
S flexneri 2a Ab IgG, Day 85/169——41.4 (23.3 to 73.6)
S flexneri 2a Ab IgG, Day 113473.6 (351.1 to 638.8)——
S flexneri 2a Ab IgG, Day 197—451.0 (327.8 to 620.6)—
S flexneri 2a Ab IgG, Day 113/197——43.8 (25.1 to 76.3)
S flexneri 3a Ab IgG, Day 117.3 (11.1 to 27.0)14.2 (8.4 to 23.9)19.9 (13.1 to 30.2)
S flexneri 3a Ab IgG, Day 1559.1 (40.5 to 86.1)63.8 (36.2 to 112.4)18.4 (12.2 to 27.8)
S flexneri 3a Ab IgG, Day 2956.7 (37.6 to 85.4)60.6 (34.8 to 105.5)19.3 (12.7 to 29.4)
S flexneri 3a Ab IgG, Day 8526.9 (16.7 to 43.4)——
S flexneri 3a Ab IgG, Day 169—24.7 (14.1 to 43.2)—
S flexneri 3a Ab IgG, Day 85/169——10.1 (6.4 to 15.9)
S flexneri 3a Ab IgG, Day 11343.1 (26.9 to 69.2)——
S flexneri 3a Ab IgG, Day 197—37.2 (22.4 to 61.7)—
S flexneri 3a Ab IgG, Day 113/197——9.2 (5.6 to 15.0)
SecondaryStage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 18 to 50 Years of Age in Africa
Time frame:
At Day 1 and Day 85 (before each study intervention administration) and Day 29 and Day 113 (28 days after each study intervention administration)
Reported as:
Geometric mean · EU/mL
Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 18 to 50 Years of Age in Africa
EU/mLStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: Control
S sonnei Ab IgG, Day 1166.4 (82.8 to 334.2)171.2 (65.0 to 450.6)
S sonnei Ab IgG, Day 293112.0 (2181.6 to 4439.2)172.0 (66.7 to 443.6)
S sonnei Ab IgG, Day 852046.5 (1372.1 to 3052.5)182.1 (73.2 to 453.1)
S sonnei Ab IgG, Day 1131974.4 (1288.5 to 3025.6)172.3 (68.8 to 431.6)
S flexneri 1b Ab IgG, Day 1194.7 (44.0 to 862.2)106.4 (41.0 to 276.2)
S flexneri 1b Ab IgG, Day 29388.5 (98.6 to 1531.3)103.3 (40.2 to 265.8)
S flexneri 1b Ab IgG, Day 85328.0 (84.8 to 1268.8)110.8 (38.9 to 315.5)
S flexneri 1b Ab IgG, Day 113358.3 (98.6 to 1301.7)107.2 (37.5 to 306.1)
S flexneri 2a Ab IgG, Day 1192.3 (93.7 to 394.6)155.8 (70.7 to 343.6)
S flexneri 2a Ab IgG, Day 29563.0 (269.1 to 1177.7)146.1 (68.7 to 311.0)
S flexneri 2a Ab IgG, Day 85463.0 (220.3 to 973.4)158.1 (67.7 to 369.3)
S flexneri 2a Ab IgG, Day 113538.6 (269.9 to 1074.7)154.0 (68.5 to 346.2)
S flexneri 3a Ab IgG, Day 184.8 (34.5 to 208.8)61.3 (19.6 to 192.0)
S flexneri 3a Ab IgG, Day 29212.8 (89.9 to 503.6)57.4 (18.2 to 181.5)
S flexneri 3a Ab IgG, Day 85174.4 (75.1 to 405.3)62.3 (16.7 to 233.3)
S flexneri 3a Ab IgG, Day 113225.4 (103.2 to 492.7)61.6 (16.7 to 226.8)
SecondaryStage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 24 to 59 Months of Age in Africa
Time frame:
At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)
Reported as:
Geometric mean · EU/mL
Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 24 to 59 Months of Age in Africa
EU/mLStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: Control
S sonnei Ab IgG, Day 122.7 (8.5 to 61.0)39.1 (9.5 to 160.1)20.7 (10.5 to 41.0)
S sonnei Ab IgG, Day 29899.0 (122.7 to 6588.6)746.9 (93.9 to 5940.9)19.3 (10.4 to 35.8)
S sonnei Ab IgG, Day 85)702.7 (125.7 to 3927.4)388.2 (56.6 to 2663.4)24.7 (11.1 to 54.7)
S sonnei Ab IgG, Day 1131163.2 (289.8 to 4668.7)560.2 (86.0 to 3651.0)40.2 (15.9 to 101.6)
S flexneri 1b Ab IgG, Day 128.6 (6.6 to 123.1)38.4 (7.0 to 211.4)37.0 (16.4 to 83.3)
S flexneri 1b Ab IgG, Day 2974.0 (23.3 to 234.8)119.4 (27.2 to 525.1)33.4 (13.6 to 81.7)
S flexneri 1b Ab IgG, Day 8539.3 (10.7 to 144.5)65.4 (13.1 to 326.7)34.5 (15.0 to 79.6)
S flexneri 1b Ab IgG, Day 11366.7 (20.5 to 217.0)100.3 (21.6 to 466.4)31.9 (14.0 to 72.4)
S flexneri 2a Ab IgG, Day 124.5 (5.1 to 117.9)21.0 (4.7 to 93.0)30.9 (12.4 to 77.3)
S flexneri 2a Ab IgG, Day 29219.2 (65.6 to 732.9)193.5 (76.2 to 491.6)30.6 (12.7 to 74.2)
S flexneri 2a Ab IgG, Day 85101.2 (28.7 to 356.9)103.8 (36.3 to 297.0)32.1 (14.2 to 72.5)
S flexneri 2a Ab IgG, Day 113267.3 (101.0 to 707.4)290.0 (115.0 to 731.3)29.5 (13.8 to 63.2)
S flexneri 3a Ab IgG, Day 114.2 (4.5 to 44.7)8.5 (3.5 to 20.6)7.6 (3.0 to 19.8)
S flexneri 3a Ab IgG, Day 2930.7 (10.7 to 87.9)22.0 (7.6 to 63.7)6.2 (2.5 to 15.2)
S flexneri 3a Ab IgG, Day 8517.8 (5.9 to 53.4)14.1 (4.9 to 40.3)6.2 (2.7 to 14.2)
S flexneri 3a Ab IgG, Day 11332.1 (12.3 to 84.2)26.1 (10.2 to 66.7)7.0 (3.2 to 15.6)
SecondaryStage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 9 Months of Age in Africa - Infants Safety Cohort
Time frame:
At Day 1, Day 85 and Day 253 (before each study intervention administration) and Day 29, Day 113 and Day 281 (28 days after each study intervention administration)
Reported as:
Geometric mean · EU/mL
Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 9 Months of Age in Africa - Infants Safety Cohort
EU/mLStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: Control
S sonnei Ab IgG, Day 16.4 (6.4 to 6.4)6.9 (5.8 to 8.1)6.4 (6.4 to 6.4)6.6 (6.2 to 6.9)
S sonnei Ab IgG, Day 2916.9 (7.8 to 36.6)17.5 (9.5 to 32.4)17.3 (9.1 to 33.0)6.4 (6.4 to 6.4)
S sonnei Ab IgG, Day 8527.2 (12.6 to 58.3)32.7 (16.1 to 66.6)23.3 (11.1 to 48.9)6.4 (6.4 to 6.4)
S sonnei Ab IgG, Day 113240.4 (60.3 to 958.3)264.7 (105.1 to 666.9)171.0 (67.7 to 431.6)6.4 (6.4 to 6.4)
S sonnei Ab IgG, Day 253128.5 (60.1 to 274.9)99.5 (50.4 to 196.3)63.4 (24.4 to 165.1)6.4 (6.4 to 6.4)
S sonnei Ab IgG, Day 281429.9 (155.7 to 1186.8)275.8 (90.1 to 844.3)185.2 (111.2 to 308.4)6.4 (6.4 to 6.4)
S flexneri 1b Ab IgG, Day 16.0 (2.5 to 14.8)6.4 (3.9 to 10.6)4.2 (2.4 to 7.4)5.9 (4.1 to 8.5)
S flexneri 1b Ab IgG, Day 2924.2 (8.2 to 71.2)18.5 (10.6 to 32.3)7.0 (3.1 to 16.0)6.3 (4.6 to 8.6)
S flexneri 1b Ab IgG, Day 8516.3 (6.7 to 40.0)9.4 (4.9 to 17.8)6.3 (3.1 to 12.7)7.4 (5.0 to 10.9)
S flexneri 1b Ab IgG, Day 11330.5 (8.6 to 108.0)18.2 (12.1 to 27.5)14.2 (5.0 to 40.2)7.4 (5.0 to 10.9)
S flexneri 1b Ab IgG, Day 2539.0 (3.5 to 23.2)7.2 (3.2 to 16.1)8.9 (4.5 to 17.3)7.4 (5.0 to 10.9)
S flexneri 1b Ab IgG, Day 28123.3 (9.5 to 57.0)20.4 (8.1 to 51.2)29.4 (15.3 to 56.6)8.0 (5.3 to 12.0)
S flexneri 2a Ab IgG, Day 13.6 (1.5 to 9.0)4.4 (2.3 to 8.3)3.9 (1.8 to 8.4)4.1 (2.2 to 7.4)
S flexneri 2a Ab IgG, Day 2934.6 (11.0 to 109.1)40.5 (16.3 to 100.6)17.1 (6.0 to 49.0)4.6 (2.5 to 8.4)
S flexneri 2a Ab IgG, Day 8529.6 (11.5 to 76.6)16.4 (7.4 to 36.3)9.7 (3.8 to 24.7)5.8 (3.2 to 10.6)
S flexneri 2a Ab IgG, Day 11381.6 (38.9 to 171.1)77.4 (31.1 to 192.5)65.5 (33.0 to 130.0)7.2 (3.6 to 14.2)
S flexneri 2a Ab IgG, Day 2539.9 (2.5 to 38.8)11.2 (2.7 to 47.6)14.4 (5.2 to 40.1)7.7 (3.9 to 15.2)
S flexneri 2a Ab IgG, Day 281135.0 (81.6 to 223.1)72.5 (24.6 to 213.7)110.7 (60.4 to 203.0)8.2 (4.4 to 15.2)
S flexneri 3a Ab IgG, Day 12.7 (1.3 to 5.6)5.1 (2.7 to 9.7)2.6 (1.4 to 4.7)3.3 (2.2 to 5.0)
S flexneri 3a Ab IgG, Day 299.6 (3.4 to 26.9)8.9 (3.1 to 25.2)3.5 (1.7 to 7.3)3.4 (2.2 to 5.2)
S flexneri 3a Ab IgG, Day 855.1 (2.2 to 12.2)6.0 (2.4 to 15.1)2.1 (1.1 to 4.2)4.0 (2.5 to 6.4)
S flexneri 3a Ab IgG, Day 11312.5 (4.0 to 38.4)7.9 (2.5 to 25.1)4.5 (2.3 to 8.8)3.8 (2.4 to 5.8)
S flexneri 3a Ab IgG, Day 2536.8 (2.4 to 19.2)8.5 (2.0 to 35.6)3.2 (1.6 to 6.5)4.5 (2.8 to 7.0)
S flexneri 3a Ab IgG, Day 28123.0 (7.0 to 75.8)20.4 (5.2 to 79.7)13.2 (3.5 to 49.8)4.9 (3.1 to 7.9)
SecondaryStage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 9 Months of Age in Africa - Dose-finding Cohort
Time frame:
At Day 1, Day 85 and Day 253 (before each study intervention administration) and Day 29, Day 113 and Day 281 (28 days after each study intervention administration)
Reported as:
Geometric mean · EU/mL
Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 9 Months of Age in Africa - Dose-finding Cohort
EU/mLStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
S sonnei Ab IgG, Day 110.9 (8.9 to 13.2)9.5 (8.1 to 11.0)10.7 (8.7 to 13.3)9.8 (8.2 to 11.6)
S sonnei Ab IgG, Day 2936.0 (27.4 to 47.4)41.9 (33.6 to 52.4)38.5 (29.0 to 51.3)9.5 (8.1 to 11.1)
S sonnei Ab IgG, Day 8541.7 (32.3 to 53.9)46.7 (36.8 to 59.2)41.1 (33.5 to 50.6)8.2 (6.9 to 9.7)
S sonnei Ab IgG, Day 113313.6 (224.5 to 438.1)353.4 (244.7 to 510.4)328.7 (235.4 to 459.1)9.0 (7.2 to 11.3)
S sonnei Ab IgG, Day 253162.1 (128.9 to 203.8)195.3 (154.9 to 246.2)219.0 (164.3 to 291.8)16.9 (12.5 to 22.8)
S sonnei Ab IgG, Day 281446.3 (342.1 to 582.3)535.1 (416.2 to 688.0)603.8 (461.4 to 790.2)18.6 (13.7 to 25.2)
S flexneri 1b Ab IgG, Day 111.4 (8.5 to 15.4)11.8 (8.7 to 15.9)12.6 (9.1 to 17.3)13.4 (9.9 to 18.0)
S flexneri 1b Ab IgG, Day 2932.9 (23.7 to 45.6)47.5 (34.8 to 64.9)36.8 (26.5 to 51.0)13.4 (10.0 to 18.0)
S flexneri 1b Ab IgG, Day 8513.0 (9.9 to 17.0)11.1 (8.5 to 14.4)9.6 (7.5 to 12.3)8.1 (6.2 to 10.7)
S flexneri 1b Ab IgG, Day 11325.4 (18.5 to 34.8)21.2 (17.4 to 25.8)20.6 (16.4 to 25.8)7.4 (5.7 to 9.5)
S flexneri 1b Ab IgG, Day 25315.7 (11.6 to 21.3)9.3 (7.4 to 11.7)10.3 (7.8 to 13.5)16.9 (11.7 to 24.2)
S flexneri 1b Ab IgG, Day 28157.3 (43.2 to 76.0)34.4 (26.6 to 44.3)36.7 (28.1 to 47.9)16.6 (11.5 to 23.9)
S flexneri 2a Ab IgG, Day 16.1 (4.6 to 8.2)5.2 (4.0 to 6.6)6.2 (4.7 to 8.2)5.7 (4.4 to 7.5)
S flexneri 2a Ab IgG, Day 2951.6 (38.1 to 69.9)58.2 (42.6 to 79.5)59.4 (42.2 to 83.7)6.2 (4.7 to 8.2)
S flexneri 2a Ab IgG, Day 8520.0 (14.0 to 28.6)12.7 (9.2 to 17.7)14.4 (10.1 to 20.6)4.7 (3.2 to 6.7)
S flexneri 2a Ab IgG, Day 11395.4 (72.4 to 125.5)69.9 (52.2 to 93.7)84.4 (62.4 to 114.2)4.5 (3.2 to 6.4)
S flexneri 2a Ab IgG, Day 25327.5 (19.9 to 38.1)19.5 (15.3 to 25.0)23.2 (18.0 to 30.0)11.8 (8.2 to 17.1)
S flexneri 2a Ab IgG, Day 281189.2 (139.2 to 257.2)142.3 (112.6 to 179.7)177.9 (134.7 to 234.9)12.1 (8.3 to 17.4)
S flexneri 3a Ab IgG, Day 18.1 (5.3 to 12.5)5.4 (3.7 to 7.9)6.3 (4.1 to 9.6)10.2 (6.6 to 15.8)
S flexneri 3a Ab IgG, Day 2922.4 (15.2 to 33.0)19.1 (12.8 to 28.5)14.8 (9.7 to 22.6)10.0 (6.3 to 15.8)
S flexneri 3a Ab IgG, Day 8511.1 (7.3 to 16.6)11.4 (7.7 to 16.8)6.6 (4.5 to 9.8)8.5 (5.5 to 13.2)
S flexneri 3a Ab IgG, Day 11325.7 (17.3 to 38.3)18.4 (12.2 to 27.7)16.0 (11.2 to 22.9)7.7 (5.2 to 11.5)
S flexneri 3a Ab IgG, Day 25313.5 (9.8 to 18.7)8.8 (6.6 to 11.8)9.6 (6.9 to 13.2)10.7 (7.4 to 15.5)
S flexneri 3a Ab IgG, Day 28145.7 (34.0 to 61.5)28.1 (21.1 to 37.4)36.3 (27.0 to 48.8)10.9 (7.4 to 16.1)
SecondaryStage 1: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg
Time frame:
At Day 1 and Day 85/Day 169 (before each study intervention); at Day 15 (14 days after the first study intervention); at Day 29 and Day 113/Day 197 (28 days after each study intervention)
Reported as:
Count of participants · Participants
Stage 1: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg
ParticipantsStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo Group
Day 1105
Day 1522194
Day 2922184
Day 8517——
Day 169—14—
Day 85/169——3
Day 11321——
Day 197—22—
Day 113/197——3
SecondaryStage 2: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg
Time frame:
At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg
ParticipantsStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: Control
Day 175
Day 29105
Day 85106
Day 113105
SecondaryStage 2: Number of Participants 24 to 59 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg
Time frame:
At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 24 to 59 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg
ParticipantsStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: Control
Day 1243
Day 29762
Day 85763
Day 113765
SecondaryStage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/Oag - Safety Cohort
Time frame:
At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/Oag - Safety Cohort
ParticipantsStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: Control
Day 10000
Day 290000
Day 850100
Day 1136650
Day 2534230
Day 2816660
SecondaryStage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/Oag - Dose-finding Cohort
Time frame:
At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/Oag - Dose-finding Cohort
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
Day 11021
Day 291011120
Day 859961
Day 1135152572
Day 2534248498
Day 2816161678
SecondaryStage 1: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg
Time frame:
At Day 1 and Day 85/Day 169 (before each study intervention); at Day 15 (14 days after the first study intervention); at Day 29 and Day 113/Day 197 (28 days after each study intervention)
Reported as:
Count of participants · Participants
Stage 1: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg
ParticipantsStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo Group
Day 1102
Day 1513112
Day 2912112
Day 8512——
Day 169—9—
Day 85/169——2
Day 11311——
Day 197—10—
Day 113/197——2
SecondaryStage 2: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg
Time frame:
At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg
ParticipantsStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: Control
Day 123
Day 29103
Day 85103
Day 113102
SecondaryStage 2: Number of Participants 24 to 59 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg
Time frame:
At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 24 to 59 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg
ParticipantsStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: Control
Day 1011
Day 29760
Day 85761
Day 113763
SecondaryStage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg - Safety Cohort
Time frame:
At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg - Safety Cohort
ParticipantsStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: Control
Day 10000
Day 290000
Day 850000
Day 1135330
Day 2533000
Day 2815320
SecondaryStage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg - Dose-finding Cohort
Time frame:
At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg - Dose-finding Cohort
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
Day 11020
Day 292020
Day 852211
Day 1133836361
Day 2531820282
Day 2814045472
SecondaryStage 1: Number of Participants 18 to 50 Years of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA
Time frame:
At Day 15 (14 days after the first study intervention) and at Day 29 and Day 113/Day 197 (28 days after each study intervention) compared to baseline (Day 1 and Day 85/Day 169)
Reported as:
Count of participants · Participants
Stage 1: Number of Participants 18 to 50 Years of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA
ParticipantsStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo Group
S sonnei Ab IgG, Day 15 compared to Day 125270
S sonnei Ab IgG, Day 29 compared to Day 126260
S sonnei Ab IgG, Day 85 compared to Day 122——
S sonnei Ab IgG, Day 113 compared to Day 122——
S sonnei Ab IgG, Day 113 compared to Day 850——
S sonnei Ab IgG, Day 169 compared to Day 1—21—
S sonnei Ab IgG, Day 85/169 compared to Day 1——0
S sonnei Ab IgG, Day 197 compared to Day 1—26—
S sonnei Ab IgG, Day 197 compared to Day 169—4—
S sonnei Ab IgG, Day 113/197 compared to Day 1——0
S sonnei Ab IgG, Day 113/197 compared to Day 85/169——0
S flexneri 1b Ab IgG, Day 15 compared to Day 117160
S flexneri 1b Ab IgG, Day 29 compared to Day 115140
S flexneri 1b Ab IgG, Day 85 compared to Day 17——
S flexneri 1b Ab IgG, Day 113 compared to Day 111——
S flexneri 1b Ab IgG, Day 113 compared to Day 852——
S flexneri 1b Ab IgG, Day 169 compared to Day 1—5—
S flexneri 1b Ab IgG, Day 85/169 compared to Day 1——0
S flexneri 1b Ab IgG, Day 197 compared to Day 1—10—
S flexneri 1b Ab IgG, Day 197 compared to Day 169—1—
S flexneri 1b Ab IgG, Day 113/197 compared to Day 1——0
S flexneri 1b Ab IgG, Day 113/197 compared to Day 85/169——0
S flexneri 2a Ab IgG, Day 15 compared to Day 132310
S flexneri 2a Ab IgG, Day 29 compared to Day 130310
S flexneri 2a Ab IgG, Day 85 compared to Day 127——
S flexneri 2a Ab IgG, Day 113 compared to Day 126——
S flexneri 2a Ab IgG, Day 113 compared to Day 851——
S flexneri 2a Ab IgG, Day 169 compared to Day 1—31—
S flexneri 2a Ab IgG, Day 85/169 compared to Day 1——0
S flexneri 2a Ab IgG, Day 197 compared to Day 1—32—
S flexneri 2a Ab IgG, Day 197 compared to Day 169—0—
S flexneri 2a Ab IgG, Day 113/197 compared to Day 1——0
S flexneri 2a Ab IgG, Day 113/197 compared to Day 85/169——1
S flexneri 3a Ab IgG, Day 15 compared to Day 112170
S flexneri 3a Ab IgG, Day 29 compared to Day 112170
S flexneri 3a Ab IgG, Day 85 compared to Day 12——
S flexneri 3a Ab IgG, Day 169 compared to Day 1—4—
S flexneri 3a Ab IgG, Day 85/169 compared to Day 1——0
S flexneri 3a Ab IgG, Day 113 compared to Day 16——
S flexneri 3a Ab IgG, Day 113 compared to Day 853——
S flexneri 3a Ab IgG, Day 197 compared to Day 1—9—
S flexneri 3a Ab IgG, Day 197 compared to Day 169—1—
S flexneri 3a Ab IgG, Day 113/197 compared to Day 1——0
S flexneri 3a Ab IgG, Day 113/197 compared to Day 85/169——0
SecondaryStage 2: Number of Participants 18 to 50 Years of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA
Time frame:
At Day 29 and Day 113 (28 days after each study intervention) compared to baseline (Day 1 and Day 85)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 18 to 50 Years of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA
ParticipantsStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: Control
S sonnei Ab IgG, Day 29 compared to Day 1100
S sonnei Ab IgG, Day 85 compared to Day 1100
S sonnei Ab IgG, Day 113 compared to Day 1100
S Sonnei Ab IgG, Day 113 compared to Day 8500
S flexneri 1b Ab IgG, Day 29 compared to Day 120
S flexneri 1b Ab IgG, Day 85 compared to Day 110
S flexneri 1b Ab IgG, Day 113 compared to Day 110
S flexneri 1b Ab IgG, Day 113 compared to Day 8500
S flexneri 2a Ab IgG, Day 29 compared to Day 130
S flexneri 2a Ab IgG, Day 85 compared to Day 120
S flexneri 2a Ab IgG, Day 113 compared to Day 130
S flexneri 2a Ab IgG, Day 113 compared to Day 8500
S flexneri 3a Ab IgG, Day 29 compared to Day 140
S flexneri 3a Ab IgG, Day 85 compared to Day 120
S flexneri 3a Ab IgG, Day 113 compared to Day 130
S flexneri 3a Ab IgG, Day 113 compared to Day 8500
SecondaryStage 2: Number of Participants 24 to 59 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA
Time frame:
At Day 29 and Day 113 (28 days after each study intervention) compared to baseline (Day 1 and Day 85)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 24 to 59 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA
ParticipantsStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: Control
S sonnei Ab IgG, Day 29 compared to Day 1751
S sonnei Ab IgG, Day 85 compared to Day 1753
S sonnei Ab IgG, Day 113 compared to Day 11065
S sonnei Ab IgG, Day 113 compared to Day 85113
S flexneri 1b Ab IgG, Day 29 compared to Day 1241
S flexneri 1b Ab IgG, Day 85 compared to Day 1011
S flexneri 1b Ab IgG, Day 113 compared to Day 1231
S flexneri 1b Ab IgG, Day 113 compared to Day 85001
S flexneri 2a Ab IgG, Day 29 compared to Day 1660
S flexneri 2a Ab IgG, Day 85 compared to Day 1351
S flexneri 2a Ab IgG, Day 113 compared to Day 17100
S flexneri 2a Ab IgG, Day 113 compared to Day 85320
S flexneri 3a Ab IgG, Day 29 compared to Day 1030
S flexneri 3a Ab IgG, Day 85 compared to Day 1010
S flexneri 3a Ab IgG, Day 113 compared to Day 1131
S flexneri 3a Ab IgG, Day 113 compared to Day 85001
SecondaryStage 2: Number of Participants 9 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA - Safety Cohort
Time frame:
At Day 29, Day 113 and Day 281 (28 days after each study intervention) compared to baseline (Day 1, Day 85 and Day 253)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA - Safety Cohort
ParticipantsStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: Control
S sonnei Ab IgG, Day 29 compared to Day 12010
S sonnei Ab IgG, Day 85 compared to Day 12130
S sonnei Ab IgG, Day 113 compared to Day 18890
S sonnei Ab IgG, Day 113 compared to Day 857670
S sonnei Ab IgG, Day 253 compared to Day 18660
S sonnei Ab IgG, Day 281 compared to Day 19790
S sonnei Ab IgG, Day 281 compared to Day 2533220
S flexneri 1b Ab IgG, Day 29 compared to Day 13110
S flexneri 1b Ab IgG, Day 85 compared to Day 11003
S flexneri 1b Ab IgG, Day 113 compared to Day 13023
S flexneri 1b Ab IgG, Day 113 compared to Day 852021
S flexneri 1b Ab IgG, Day 253 compared to Day 11015
S flexneri 1b Ab IgG, Day 281 compared to Day 13243
S flexneri 1b Ab IgG, Day 281 compared to Day 2531120
S flexneri 2a Ab IgG, Day 29 compared to Day 16553
S flexneri 2a Ab IgG, Day 85 compared to Day 14333
S flexneri 2a Ab IgG, Day 113 compared to Day 18696
S flexneri 2a Ab IgG, Day 113 compared to Day 851453
S flexneri 2a Ab IgG, Day 253 compared to Day 12248
S flexneri 2a Ab IgG, Day 281 compared to Day 18777
S flexneri 2a Ab IgG, Day 281 compared to Day 2536570
S flexneri 3a Ab IgG, Day 29 compared to Day 14202
S flexneri 3a Ab IgG, Day 85 compared to Day 10002
S flexneri 3a Ab IgG, Day 113 compared to Day 13101
S flexneri 3a Ab IgG, Day 113 compared to Day 852000
S flexneri 3a Ab IgG, Day 253 compared to Day 12203
S flexneri 3a Ab IgG, Day 281 compared to Day 14432
S flexneri 3a Ab IgG, Day 281 compared to Day 2533131
SecondaryStage 2: Number of Participants 9 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA - Dose-finding Cohort
Time frame:
At Day 29, Day 113 and Day 281 (28 days after each study intervention) compared to baseline (Day 1, Day 85 and Day 253)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA - Dose-finding Cohort
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
S sonnei Ab IgG, Day 29 compared to Day 12030240
S sonnei Ab IgG, Day 85 compared to Day 12829203
S sonnei Ab IgG, Day 113 compared to Day 15761642
S sonnei Ab IgG, Day 113 compared to Day 851915150
S sonnei Ab IgG, Day 253 compared to Day 153605811
S sonnei Ab IgG, Day 281 compared to Day 162626912
S sonnei Ab IgG, Day 281 compared to Day 2537481
S flexneri 1b Ab IgG, Day 29 compared to Day 12224183
S flexneri 1b Ab IgG, Day 85 compared to Day 17953
S flexneri 1b Ab IgG, Day 113 compared to Day 11713111
S flexneri 1b Ab IgG, Day 113 compared to Day 855241
S flexneri 1b Ab IgG, Day 253 compared to Day 1103412
S flexneri 1b Ab IgG, Day 281 compared to Day 131292513
S flexneri 1b Ab IgG, Day 281 compared to Day 2531915131
S flexneri 2a Ab IgG, Day 29 compared to Day 15052493
S flexneri 2a Ab IgG, Day 85 compared to Day 12224248
S flexneri 2a Ab IgG, Day 113 compared to Day 15452587
S flexneri 2a Ab IgG, Day 113 compared to Day 853936423
S flexneri 2a Ab IgG, Day 253 compared to Day 130272918
S flexneri 2a Ab IgG, Day 281 compared to Day 159596516
S flexneri 2a Ab IgG, Day 281 compared to Day 2534148523
S flexneri 3a Ab IgG, Day 29 compared to Day 11525143
S flexneri 3a Ab IgG, Day 85 compared to Day 11320910
S flexneri 3a Ab IgG, Day 113 compared to Day 12625229
S flexneri 3a Ab IgG, Day 113 compared to Day 85168142
S flexneri 3a Ab IgG, Day 253 compared to Day 117151618
S flexneri 3a Ab IgG, Day 281 compared to Day 136364117
S flexneri 3a Ab IgG, Day 281 compared to Day 2532218302
SecondaryStage 2: Anti-measles IgG Concentrations in Participants 9 Months of Age in the Dose-finding Cohort
Time frame:
At Day 1 (before first measles and rubella vaccine (MR-VAC)) and at Day 281 (28 days after the second MR-VAC administration)
Reported as:
Geometric mean · mIU/mL
Stage 2: Anti-measles IgG Concentrations in Participants 9 Months of Age in the Dose-finding Cohort
mIU/mLStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
Day 126.2 (23.8 to 28.9)25.4 (24.6 to 26.1)25 (25 to 25)26.2 (24.5 to 28.1)
Day 2811204.4 (1043.2 to 1390.6)1099.7 (957.2 to 1263.4)1142.5 (983 to 1327.9)971.4 (793.2 to 1189.7)
SecondaryStage 2: Anti-rubella IgG Concentrations in Participants 9 Months of Age in the Dose-finding Groups
Time frame:
At Day 1 (before first measles and rubella vaccine (MR-VAC)) and at Day 281 (28 days after the second MR-VAC administration)
Reported as:
Geometric mean · mIU/mL
Stage 2: Anti-rubella IgG Concentrations in Participants 9 Months of Age in the Dose-finding Groups
mIU/mLStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
Day 11.2 (1 to 1.4)1 (1 to 1)1.1 (1 to 1.3)1.1 (1 to 1.1)
Day 281138.2 (124.7 to 153.1)110.3 (99.6 to 122.1)116.4 (105.1 to 129)107.1 (89.9 to 127.5)
SecondaryStage 2: Number of Participants 9 Months of Age in the Dose-finding Groups Achieving Anti-measles IgG Concentrations of ≥150 Milli International Units Per Milliliter (mIU/mL) and ≥200 mIU/mL
Time frame:
Day 281 (28 days after the second MR-VAC administration)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in the Dose-finding Groups Achieving Anti-measles IgG Concentrations of ≥150 Milli International Units Per Milliliter (mIU/mL) and ≥200 mIU/mL
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
>= 150 mIU/mL, Day 28166647168
>= 200 mIU/mL, Day 28166647167
SecondaryStage 2: Number of Participants 9 Months of Age in the Dose-finding Groups Achieving Anti-rubella IgG Concentrations of ≥4 mIU/mL and ≥10 mIU/mL
Time frame:
Day 281 (28 days after the second MR-VAC administration)
Reported as:
Count of participants · Participants
Stage 2: Number of Participants 9 Months of Age in the Dose-finding Groups Achieving Anti-rubella IgG Concentrations of ≥4 mIU/mL and ≥10 mIU/mL
ParticipantsStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
>= 4 IU/mL Day 28166647168
>= 10 IU/mL Day 28166647168

Adverse events

Collected over Solicited AEs were collected within 7 days and unsolicited AEs within 28 days after any intervention (administered on Day (D) 1 and D85 for Stage 1 adults, Stage 2 adults and children and D1, D85 and D253 for Stage 2 infants). SAEs and all-cause mortality: from Day (D) 1 to D113/D197 for stage 1, from D1 to D113 for Stage 2 adults & children, from D1 to D281 for Stage 2 infants.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 1 Adults: altSonflex1-2-3 High Dose Group 10/34 (0%)0/34 (0%)33/34 (97.1%)
Stage 1 Adults: altSonflex1-2-3 High Dose Group 20/34 (0%)1/34 (2.9%)33/34 (97.1%)
Stage 1 Adults: Placebo Group0/34 (0%)0/34 (0%)32/34 (94.1%)
Stage 2 Adults: altSonflex1-2-3 High Dose0/10 (0%)0/10 (0%)7/10 (70%)
Stage 2 Adults: Control0/10 (0%)0/10 (0%)5/10 (50%)
Stage 2 Children: altSonflex1-2-3 Medium Dose0/10 (0%)0/10 (0%)9/10 (90%)
Stage 2 Children: altSonflex1-2-3 High Dose0/10 (0%)0/10 (0%)5/10 (50%)
Stage 2 Children: Control0/20 (0%)0/20 (0%)12/20 (60%)
Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose0/10 (0%)0/10 (0%)6/10 (60%)
Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose0/10 (0%)0/10 (0%)8/10 (80%)
Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose0/10 (0%)0/10 (0%)10/10 (100%)
Stage 2 Infants Safety Cohort: Control0/30 (0%)1/30 (3.3%)26/30 (86.7%)
Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose0/82 (0%)2/82 (2.4%)77/82 (93.9%)
Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose1/81 (1.2%)1/81 (1.2%)74/81 (91.4%)
Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose0/83 (0%)4/83 (4.8%)80/83 (96.4%)
Stage 2 Infants Dose-finding Cohort: Control0/82 (0%)1/82 (1.2%)69/82 (84.1%)
Most frequent serious events
Most frequent serious events
EventStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo GroupStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: ControlStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: ControlStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: ControlStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
PneumoniaInfections and infestations0/340/340/340/100/100/100/100/200/100/100/101/301/820/811/830/82
FaecalomaGastrointestinal disorders0/341/340/340/100/100/100/100/200/100/100/100/300/820/810/830/82
GastroenteritisInfections and infestations0/340/340/340/100/100/100/100/200/100/100/100/300/821/811/830/82
EpilepsyNervous system disorders0/340/340/340/100/100/100/100/200/100/100/100/301/820/810/830/82
Infantile spasmsNervous system disorders0/340/340/340/100/100/100/100/200/100/100/100/300/820/810/831/82
StomatitisGastrointestinal disorders0/340/340/340/100/100/100/100/200/100/100/100/300/820/811/830/82
Oral candidiasisInfections and infestations0/340/340/340/100/100/100/100/200/100/100/100/300/820/811/830/82
Thermal burnInjury, poisoning and procedural complications0/340/340/340/100/100/100/100/200/100/100/100/300/820/811/830/82
Most frequent other events
Showing 10 of 151
Most frequent other events
EventStage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo GroupStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: ControlStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: ControlStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: ControlStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: Control
Administration site painGeneral disorders33/3433/3420/347/104/107/103/103/204/105/107/107/3049/8257/8158/8335/82
Administration site erythemaGeneral disorders5/348/341/340/100/101/101/100/200/101/106/101/3020/8221/8132/8314/82
Administration site swellingGeneral disorders5/349/340/340/100/101/101/100/201/102/105/105/3030/8232/8134/8320/82
PyrexiaGeneral disorders2/341/341/340/100/102/102/103/201/103/105/109/3038/8228/8137/8318/82
RhinitisInfections and infestations0/342/340/340/100/101/100/102/202/102/104/106/307/829/816/8313/82
HeadacheNervous system disorders12/3410/348/343/101/100/100/100/200/100/100/100/300/820/810/830/82
Upper respiratory tract infectionInfections and infestations2/340/342/340/101/102/100/101/202/101/102/108/3017/8219/8118/8321/82
Iron deficiency anaemiaBlood and lymphatic system disorders0/340/340/340/100/100/100/100/200/102/101/100/300/820/810/830/82
ThrombocytosisBlood and lymphatic system disorders0/340/340/340/100/100/100/100/200/102/100/100/300/820/810/830/82
GastroenteritisInfections and infestations0/341/341/340/100/100/100/100/200/101/102/100/303/828/8111/838/82

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Stage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo GroupStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: ControlStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: ControlStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: ControlStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: ControlTotal
<=18 years000001010201010103082818382428
Between 18 and 65 years343434101000000000000122
>=65 years00000000000000000
Sex: Female, Male
Sex: Female, Male(Participants)Stage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo GroupStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: ControlStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: ControlStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: ControlStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: ControlTotal
Female2827276644117541632434149310
Male677446693561450384233240
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Stage 1 Adults: altSonflex1-2-3 High Dose Group 1Stage 1 Adults: altSonflex1-2-3 High Dose Group 2Stage 1 Adults: Placebo GroupStage 2 Adults: altSonflex1-2-3 High DoseStage 2 Adults: ControlStage 2 Children: altSonflex1-2-3 Medium DoseStage 2 Children: altSonflex1-2-3 High DoseStage 2 Children: ControlStage 2 Infants Safety Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Safety Cohort: altSonflex1-2-3 High DoseStage 2 Infants Safety Cohort: ControlStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium DoseStage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High DoseStage 2 Infants Dose-finding Cohort: ControlTotal
BLACK OR AFRICAN AMERICAN00010101010201010103082818382448
WHITE3434340000000000000102
08

Study locations

2 sites
  • GSK Investigational Site
    Ghent, 9000, Belgium
  • GSK Investigational Site
    Kericho, 20200, Kenya
09

References and documents

Publications

  • Leroux-Roels I, Maes C, Mancini F, Jacobs B, Sarakinou E, Alhatemi A, Joye J, Grappi S, Cilio GL, Serry-Bangura A, Vitali CG, Ferruzzi P, Marchetti E, Necchi F, Rappuoli R, De Ryck I, Auerbach J, Colucci AM, Rossi O, Conti V, Scorza FB, Arora AK, Micoli F, Podda A, Nakakana UN; Shigella Project Team. Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study. J Infect Dis. 2024 Oct 16;230(4):e971-e984. doi: 10.1093/infdis/jiae273. PubMed 38853614 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jun 2025, 44 months.

Results were first posted in Jun 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2021
First posted
Oct 11, 2021
StartActual
Oct 6, 2021
Primary completionActual
Jun 24, 2025
CompletionActual
Jun 24, 2025
Results first posted
Jun 22, 2026
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05073003
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 11, 2021
Start date
Oct 6, 2021
Primary completion
Jun 24, 2025
Completion
Jun 24, 2025
Results posted
Jun 22, 2026
Last update
Jun 22, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion